Science & Technology 
Science and Technology
Science and Technology 
Thu, February 12, 2009
Wed, February 11, 2009
Clarient to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference on Wednesday, February 18th
ALISO VIEJO, Calif.--([ BUSINESS WIRE ])--[ Clarient, Inc. ] (Nasdaq:CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists and the pharmaceutical industry, today announced that [ Ron Andrews ], CEO and Vice Chairman of the Board of Directors, will present at the [ Roth Capital Partners 21 ][ st ][ Annual OC Growth Stock Conference ] at The Ritz-Carlton in Dana Point, CA on Wednesday, February 18, 2009 at 12:00 p.m. PT. This conference is designed to provide investors with a unique opportunity to gain insight into leading companies across all sectors.
Mr. Andrews will provide attendees with an overview about Clarient's growth strategies and will highlight the value and investment opportunity that Clarient represents. In addition, Mr. Andrews will discuss Clarient's full menu of advanced diagnostic services that analyze and characterize cancer and bring clarity to a complex disease. For those unable to attend the conference, a webcast will be available at [ www.clarientinc.com/investor ].
About Clarient
Clarient combines innovative technologies with world-class expertise to assess and characterize cancer. Clarient's mission is to provide the services, resources and critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and drug development services available both onsite and over the web. Clarient is a [ Safeguard Scientifics ] partner company. [ www.clarientinc.com ]
About Safeguard Scientifics
Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE:SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 million and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. [ www.safeguard.com ]